{
  "first_published_at": "2011-08-08", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON125971", 
  "title": "Vimpat▼ (lacosamide) 15 mg/mL syrup: recall due to quality defect", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\"]}", 
  "_document_number": 144, 
  "label": null, 
  "icon": null, 
  "therapeutic_area": [
    "neurology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Vimpat&#9660; (lacosamide) 15 mg/mL syrup: recall due to quality defect</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Vimpat 15 mg/mL syrup for the treatment of partial-onset seizures will be recalled because of a quality defect in some batches, leading to an uneven distribution of the active substance lacosamide.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Vimpat 15 mg/mL syrup for the treatment of partial-onset seizures will be recalled because of a quality defect in some batches, leading to an uneven distribution of the active substance lacosamide. The recall will begin on Sept 15, 2011, to allow sufficient time for patients to be switched to suitable alternatives (see advice below). The precipitate consists of the active substance lacosamide and is not a contamination. This quality defect affects only the syrup.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Doctors should contact their patients to switch them to Vimpat film-coated tablets if possible</li>\r\n\t\t\t\t<li>A 10 mg/mL oral solution currently authorised in the USA and undergoing authorisation in the EU may be made available on a named-patients basis for those who cannot take the tablets</li>\r\n\t\t\t\t<li>Do not start any new patients on Vimpat 15 mg/mL syrup</li>\r\n\t\t\t\t<li>Suspected adverse reactions to Vimpat should be reported on a Yellow Card at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a></li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Advice for patients:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Patients are advised not to stop the medication or change the dose without speaking to their doctor</li>\r\n\t\t\t</ul></div><p><strong>Further information:</strong></p><p>European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000035.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d126\" target=\"_blank\">statement on Vimpat 15 mg/mL recall</a></p><p>BNF section 4.8.1 <a href=\"http://bnf.org/bnf/bnf/61/3575.htm?q=epilepsy&t=search&ss=text&p=2#_hit\" target=\"_blank\">Control of epilepsies</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update vol 5 issue 1: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Vimpat 15 mg/mL syrup for the treatment of partial-onset seizures will be recalled because of a quality defect in some batches, leading to an uneven distribution of the active substance lacosamide. The recall will begin on Sept 15, 2011, to allow sufficient time for patients to be switched to suitable alternatives (see advice below). The precipitate consists of the active substance lacosamide and is not a contamination. This quality defect affects only the syrup.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Doctors should contact their patients to switch them to Vimpat film-coated tablets if possible</li>\r\n\t\t\t\t<li>A 10 mg/mL oral solution currently authorised in the USA and undergoing authorisation in the EU may be made available on a named-patients basis for those who cannot take the tablets</li>\r\n\t\t\t\t<li>Do not start any new patients on Vimpat 15 mg/mL syrup</li>\r\n\t\t\t\t<li>Suspected adverse reactions to Vimpat should be reported on a Yellow Card at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a></li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Advice for patients:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Patients are advised not to stop the medication or change the dose without speaking to their doctor</li>\r\n\t\t\t</ul></div><p><strong>Further information:</strong></p><p>European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000035.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d126\" target=\"_blank\">statement on Vimpat 15 mg/mL recall</a></p><p>BNF section 4.8.1 <a href=\"http://bnf.org/bnf/bnf/61/3575.htm?q=epilepsy&amp;t=search&amp;ss=text&amp;p=2#_hit\" target=\"_blank\">Control of epilepsies</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update vol 5 issue 1: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-08-01", 
  "date_last_modified": "2011-08-04", 
  "_assets": [], 
  "_item_id": 144, 
  "summary": "", 
  "body": "Article date: August 2011\n\nVimpat 15 mg/mL syrup for the treatment of partial-onset seizures will be recalled because of a quality defect in some batches, leading to an uneven distribution of the active substance lacosamide. The recall will begin on Sept 15, 2011, to allow sufficient time for patients to be switched to suitable alternatives (see advice below). The precipitate consists of the active substance lacosamide and is not a contamination. This quality defect affects only the syrup.\n\nAdvice for healthcare professionals:  \n  \n  * Doctors should contact their patients to switch them to Vimpat film-coated tablets if possible  \n  * A 10 mg/mL oral solution currently authorised in the USA and undergoing authorisation in the EU may be made available on a named-patients basis for those who cannot take the tablets  \n  * Do not start any new patients on Vimpat 15 mg/mL syrup  \n  * Suspected adverse reactions to Vimpat should be reported on a Yellow Card at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk/)  \n  \nAdvice for patients:  \n  \n  * Patients are advised not to stop the medication or change the dose without speaking to their doctor  \n  \nFurther information:\n\nEuropean Medicines Agency [statement on Vimpat 15 mg/mL recall](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000035.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d126)\n\nBNF section 4.8.1 [Control of epilepsies](http://bnf.org/bnf/bnf/61/3575.htm?q=epilepsy&t=search&ss=text&p=2#_hit)\n\n \n\nArticle citation: Drug Safety Update vol 5 issue 1: S1.\n"
}